Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bicara Therapeutics Inc. Common Stock (BCAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BCAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -19.27% | Avg. Invested days 7 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 900.58M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 556645 | Beta - | 52 Weeks Range 11.10 - 28.09 | Updated Date 04/1/2025 |
52 Weeks Range 11.10 - 28.09 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 381353806 | Price to Sales(TTM) - |
Enterprise Value 381353806 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 54385900 | Shares Floating 29577855 |
Shares Outstanding 54385900 | Shares Floating 29577855 | ||
Percent Insiders 0.42 | Percent Institutions - |
Analyst Ratings
Rating 4.6 | Target Price - | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bicara Therapeutics Inc. Common Stock
Company Overview
History and Background
Bicara Therapeutics is a clinical-stage biotechnology company focused on developing dual-action biologics designed to enhance the body's immune response to tumors. Founded in 2018, the company is leveraging its bifunctional antibody technology to develop a pipeline of novel cancer therapeutics. It is working to target both tumor cells and immune cells.
Core Business Areas
- Drug Development: The core business is the development and commercialization of novel bifunctional antibodies for cancer treatment.
Leadership and Structure
The company is led by CEO Claire Mazumdar, Ph.D. Organizational structure includes research, development, clinical operations, and business development teams.
Top Products and Market Share
Key Offerings
- BCA101: BCA101 is Bicara's lead product candidate, a bifunctional antibody designed to target EGFR and TGFu03b2. It is currently in Phase 1/2 clinical trials for advanced solid tumors. Market share data is not yet available due to its clinical stage. Competitors in EGFR and TGFu03b2 inhibition include companies like Merck (Erbitux), Eli Lilly (Cyramza), and Boehringer Ingelheim (fresolimumab).
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and rapidly growing market, driven by increasing cancer incidence and advances in immunotherapy and targeted therapies. High unmet medical needs create significant opportunities.
Positioning
Bicara is positioned in the oncology market with its innovative bifunctional antibody technology. The company is developing novel therapeutics that target both tumor cells and the immune system, aiming to improve efficacy and overcome resistance to existing therapies.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Bicara is targeting specific cancer types within this market, with the TAM varying depending on the indications BCA101 is ultimately approved for.
Upturn SWOT Analysis
Strengths
- Novel bifunctional antibody technology platform
- Experienced leadership team
- Promising preclinical and early clinical data for BCA101
- Strong intellectual property position
Weaknesses
- Early-stage development pipeline
- Reliance on a single lead product candidate
- High cash burn rate
- Subject to clinical trial risks and regulatory hurdles
Opportunities
- Expansion of the pipeline through additional bifunctional antibody programs
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results for BCA101 leading to accelerated approval
- Expansion into new cancer indications
Threats
- Failure of BCA101 in clinical trials
- Competition from established oncology therapies
- Regulatory setbacks
- Difficulty raising capital to fund development programs
Competitors and Market Share
Key Competitors
- Merck (MRK)
- Eli Lilly (LLY)
- Boehringer Ingelheim (Not Publicly Traded)
Competitive Landscape
Bicara faces competition from established pharmaceutical companies with approved oncology therapies. Its competitive advantage lies in its novel bifunctional antibody technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Due to being a clinical stage company, historical growth is limited to preclinical activity. Recent capital raises show increase in company activities.
Future Projections: Future growth depends on the success of its clinical trials and its ability to secure partnerships or funding to advance its pipeline.
Recent Initiatives: Advancing BCA101 through clinical trials, expanding its pipeline of bifunctional antibodies, and exploring potential partnerships.
Summary
Bicara Therapeutics is a clinical-stage company with a promising bifunctional antibody technology platform. Its success depends on the clinical trials of BCA101. Securing future funding will allow for new initiatives and partnerships. Bicara will need to monitor the competitive landscape and regulatory changes carefully.
Similar Companies
- MRK
- LLY
- BMY
- PFE
Sources and Disclaimers
Data Sources:
- Bicara Therapeutics Website
- SEC Filings
- ClinicalTrials.gov
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. The AI-based rating is subjective and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bicara Therapeutics Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-09-13 | CEO & Director Ms. Claire Mazumdar Clemon M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.bicara.com |
Full time employees 55 | Website https://www.bicara.com | ||
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.